Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease

Manuela Contin, Paolo Martinelli, Mirella Mochi, Fiorenzo Albani, Roberto Riva, Cesa Scaglione, Maurizio Dondi, Stefano Fanti, Cinzia Pettinato, Agostino Baruzzi

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the potential association between dopamine transporter (DAT) genotype, single photon emission CT (SPECT) measures using [123I]-N-ω-fluoropropyl-2β-carbomethoxy-3β -(4-iodophenyl)nortropane (123I]-FP-CIT) of striatal dopaminergic function, and oral levodopa response pattern in a cohort of patients with Parkinson disease. Methods: Thirty-six patients at different disease stages enrolled in the study. Each patient was examined by [123I]-FP-CIT SPECT and a standardized oral levodopa test on 2 separate days in a randomized order within 3 weeks. The main outcome variables were the specific-to-nonspecific tracer uptake ratio in the contralateral putamen for SPECT analysis; latency, duration, and magnitude of the motor effect; and presence of dyskinesias for the levodopa test. The variable number of tandem repeat (VNTR) polymorphisms of the gene coding for DAT were detected for each patient by standard methods. Results: Contralateral putamen [ 123I]-FP-CIT uptake ratios were similar in the patients carrying the 9-copy allele (n = 20) of the DAT VNTR compared with 10-repeat homozygotes (n = 16). No significant difference was found in levodopa main outcome variables and dyskinesia incidence between the two groups of patients stratified by DAT VNTR polymorphism. Conclusions: The study did not identify clinically relevant in vivo DAT neurochemical function phenotypes or levodopa response patterns associated with the DAT polymorphism.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalClinical Neuropharmacology
Volume27
Issue number3
DOIs
Publication statusPublished - May 2004

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Levodopa
Photons
Parkinson Disease
Minisatellite Repeats
Genes
Putamen
Dyskinesias
Nortropanes
Corpus Striatum
Homozygote
Alleles
Genotype
Phenotype
Incidence
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane

Keywords

  • Dopamine transporter gene polymorphism
  • Dyskinesias
  • Levodopa motor response
  • Parkinson disease
  • Single photon emission CT

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease. / Contin, Manuela; Martinelli, Paolo; Mochi, Mirella; Albani, Fiorenzo; Riva, Roberto; Scaglione, Cesa; Dondi, Maurizio; Fanti, Stefano; Pettinato, Cinzia; Baruzzi, Agostino.

In: Clinical Neuropharmacology, Vol. 27, No. 3, 05.2004, p. 111-115.

Research output: Contribution to journalArticle

Contin, Manuela ; Martinelli, Paolo ; Mochi, Mirella ; Albani, Fiorenzo ; Riva, Roberto ; Scaglione, Cesa ; Dondi, Maurizio ; Fanti, Stefano ; Pettinato, Cinzia ; Baruzzi, Agostino. / Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease. In: Clinical Neuropharmacology. 2004 ; Vol. 27, No. 3. pp. 111-115.
@article{57c423c424a042809d2064aa999339e1,
title = "Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease",
abstract = "Objectives: To assess the potential association between dopamine transporter (DAT) genotype, single photon emission CT (SPECT) measures using [123I]-N-ω-fluoropropyl-2β-carbomethoxy-3β -(4-iodophenyl)nortropane (123I]-FP-CIT) of striatal dopaminergic function, and oral levodopa response pattern in a cohort of patients with Parkinson disease. Methods: Thirty-six patients at different disease stages enrolled in the study. Each patient was examined by [123I]-FP-CIT SPECT and a standardized oral levodopa test on 2 separate days in a randomized order within 3 weeks. The main outcome variables were the specific-to-nonspecific tracer uptake ratio in the contralateral putamen for SPECT analysis; latency, duration, and magnitude of the motor effect; and presence of dyskinesias for the levodopa test. The variable number of tandem repeat (VNTR) polymorphisms of the gene coding for DAT were detected for each patient by standard methods. Results: Contralateral putamen [ 123I]-FP-CIT uptake ratios were similar in the patients carrying the 9-copy allele (n = 20) of the DAT VNTR compared with 10-repeat homozygotes (n = 16). No significant difference was found in levodopa main outcome variables and dyskinesia incidence between the two groups of patients stratified by DAT VNTR polymorphism. Conclusions: The study did not identify clinically relevant in vivo DAT neurochemical function phenotypes or levodopa response patterns associated with the DAT polymorphism.",
keywords = "Dopamine transporter gene polymorphism, Dyskinesias, Levodopa motor response, Parkinson disease, Single photon emission CT",
author = "Manuela Contin and Paolo Martinelli and Mirella Mochi and Fiorenzo Albani and Roberto Riva and Cesa Scaglione and Maurizio Dondi and Stefano Fanti and Cinzia Pettinato and Agostino Baruzzi",
year = "2004",
month = "5",
doi = "10.1097/00002826-200405000-00004",
language = "English",
volume = "27",
pages = "111--115",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease

AU - Contin, Manuela

AU - Martinelli, Paolo

AU - Mochi, Mirella

AU - Albani, Fiorenzo

AU - Riva, Roberto

AU - Scaglione, Cesa

AU - Dondi, Maurizio

AU - Fanti, Stefano

AU - Pettinato, Cinzia

AU - Baruzzi, Agostino

PY - 2004/5

Y1 - 2004/5

N2 - Objectives: To assess the potential association between dopamine transporter (DAT) genotype, single photon emission CT (SPECT) measures using [123I]-N-ω-fluoropropyl-2β-carbomethoxy-3β -(4-iodophenyl)nortropane (123I]-FP-CIT) of striatal dopaminergic function, and oral levodopa response pattern in a cohort of patients with Parkinson disease. Methods: Thirty-six patients at different disease stages enrolled in the study. Each patient was examined by [123I]-FP-CIT SPECT and a standardized oral levodopa test on 2 separate days in a randomized order within 3 weeks. The main outcome variables were the specific-to-nonspecific tracer uptake ratio in the contralateral putamen for SPECT analysis; latency, duration, and magnitude of the motor effect; and presence of dyskinesias for the levodopa test. The variable number of tandem repeat (VNTR) polymorphisms of the gene coding for DAT were detected for each patient by standard methods. Results: Contralateral putamen [ 123I]-FP-CIT uptake ratios were similar in the patients carrying the 9-copy allele (n = 20) of the DAT VNTR compared with 10-repeat homozygotes (n = 16). No significant difference was found in levodopa main outcome variables and dyskinesia incidence between the two groups of patients stratified by DAT VNTR polymorphism. Conclusions: The study did not identify clinically relevant in vivo DAT neurochemical function phenotypes or levodopa response patterns associated with the DAT polymorphism.

AB - Objectives: To assess the potential association between dopamine transporter (DAT) genotype, single photon emission CT (SPECT) measures using [123I]-N-ω-fluoropropyl-2β-carbomethoxy-3β -(4-iodophenyl)nortropane (123I]-FP-CIT) of striatal dopaminergic function, and oral levodopa response pattern in a cohort of patients with Parkinson disease. Methods: Thirty-six patients at different disease stages enrolled in the study. Each patient was examined by [123I]-FP-CIT SPECT and a standardized oral levodopa test on 2 separate days in a randomized order within 3 weeks. The main outcome variables were the specific-to-nonspecific tracer uptake ratio in the contralateral putamen for SPECT analysis; latency, duration, and magnitude of the motor effect; and presence of dyskinesias for the levodopa test. The variable number of tandem repeat (VNTR) polymorphisms of the gene coding for DAT were detected for each patient by standard methods. Results: Contralateral putamen [ 123I]-FP-CIT uptake ratios were similar in the patients carrying the 9-copy allele (n = 20) of the DAT VNTR compared with 10-repeat homozygotes (n = 16). No significant difference was found in levodopa main outcome variables and dyskinesia incidence between the two groups of patients stratified by DAT VNTR polymorphism. Conclusions: The study did not identify clinically relevant in vivo DAT neurochemical function phenotypes or levodopa response patterns associated with the DAT polymorphism.

KW - Dopamine transporter gene polymorphism

KW - Dyskinesias

KW - Levodopa motor response

KW - Parkinson disease

KW - Single photon emission CT

UR - http://www.scopus.com/inward/record.url?scp=2942627103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942627103&partnerID=8YFLogxK

U2 - 10.1097/00002826-200405000-00004

DO - 10.1097/00002826-200405000-00004

M3 - Article

C2 - 15190232

AN - SCOPUS:2942627103

VL - 27

SP - 111

EP - 115

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 3

ER -